Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) WACC %:10.97% (As of Aug. 24, 2026) — 10% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06990 Sichuan Kelun-Biotech Biopharmaceutical Co Ltd HKSE:06990
44 GF Score
Price HK$523.00
GF Value HK$254.91
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sichuan Kelun-Biotech Biopharmaceutical Co WACC %?

Sichuan Kelun-Biotech Biopharmaceutical Co HKSE:06990 -2.79% 44 WACC % is 10.97% as of Aug. 24, 2026, which is 10% above its 10-year median of 9.97. GuruFocus rates HKSE:06990 with a GF Score™ of 44/100 and a GF Value™ of HK$254.91 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,421 Biotechnology companies, Sichuan Kelun-Biotech Biopharmaceutical Co ranks worse than 63.34% on this metric.

As of today (2026-08-24), Sichuan Kelun-Biotech Biopharmaceutical Co's weighted average cost of capital is 10.97%%. Sichuan Kelun-Biotech Biopharmaceutical Co's ROIC % is -63.69% (calculated using TTM income statement data). Sichuan Kelun-Biotech Biopharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.

For a comprehensive WACC calculation, please access the WACC Calculator.


Sichuan Kelun-Biotech Biopharmaceutical Co  (HKSE:06990) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Sichuan Kelun-Biotech Biopharmaceutical Co's weighted average cost of capital is 10.97%%. Sichuan Kelun-Biotech Biopharmaceutical Co's ROIC % is -63.69% (calculated using TTM income statement data). Sichuan Kelun-Biotech Biopharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.


Related Terms

Sichuan Kelun-Biotech Biopharmaceutical Co WACC % Historical Data

* Premium members only.

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sichuan Kelun-Biotech Biopharmaceutical Co WACC % Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
WACC %
0.00 5.41 9.78 10.56 10.16

Sichuan Kelun-Biotech Biopharmaceutical Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.39 10.56 10.20 10.16 11.28

HKSE:06990 vs VRTX, REGN, RVMD: WACC % Comparison

For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sichuan Kelun-Biotech Biopharmaceutical Co WACC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sichuan Kelun-Biotech Biopharmaceutical Co's WACC % distribution charts can be found below:

* The bar in red indicates where Sichuan Kelun-Biotech Biopharmaceutical Co's WACC % falls into.


HKSE:06990
44GF Score
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd HKSE:06990
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sichuan Kelun-Biotech Biopharmaceutical Co WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Sichuan Kelun-Biotech Biopharmaceutical Co's market capitalization (E) is HK$125009.536 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Jun. 2026, Sichuan Kelun-Biotech Biopharmaceutical Co's latest one-year semi-annual average Book Value of Debt (D) is HK$111.6967 Mil.
a) weight of equity = E / (E + D) = 125009.536 / (125009.536 + 111.6967) = 0.9991
b) weight of debt = D / (E + D) = 111.6967 / (125009.536 + 111.6967) = 0.0009

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.704%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Sichuan Kelun-Biotech Biopharmaceutical Co's beta is 1.0458.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.704% + 1.0458 * 6% = 10.9788%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.
As of Jun. 2026, Sichuan Kelun-Biotech Biopharmaceutical Co's interest expense (positive number) was HK$5.867 Mil. Its total Book Value of Debt (D) is HK$111.6967 Mil.
Cost of Debt = 5.867 / 111.6967 = 5.2526%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = -99.506 / 87.715 = -113.44%, which is less than 0%. Therefore it's set to 0%.

Sichuan Kelun-Biotech Biopharmaceutical Co's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.9991*10.9788%+0.0009*5.2526%*(1 - 0%)
=10.97%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 10.97% mean?
Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) has a WACC % of 10.97% as of Aug. 24, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. This is 10% above median its historical median of 9.97. Over the past decade, Sichuan Kelun-Biotech Biopharmaceutical Co's WACC % has ranged from 5.41 to 11.01. According to the industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #900 out of 1421 companies in the Biotechnology industry, placing it in the top 63.3%.
Is Sichuan Kelun-Biotech Biopharmaceutical Co's WACC % too high?
Sichuan Kelun-Biotech Biopharmaceutical Co's current WACC % of 10.97% is 10% above median its 10-year median of 9.97. Over the past 10 years, this metric has ranged from a low of 5.41 to a high of 11.01. The Biotechnology industry median WACC % is 10.17. Sichuan Kelun-Biotech Biopharmaceutical Co's value of 10.97% is 7.9% above this industry median. Based on the distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #900 out of 1421 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sichuan Kelun-Biotech Biopharmaceutical Co has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Kelun-Biotech Biopharmaceutical Co's WACC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #900 out of 1421 companies for WACC %. This places Sichuan Kelun-Biotech Biopharmaceutical Co in the lower half of its industry. The industry median WACC % is 10.17. Sichuan Kelun-Biotech Biopharmaceutical Co's value of 10.97% is 7.9% above this benchmark. Historically, Sichuan Kelun-Biotech Biopharmaceutical Co's own WACC % has ranged from 5.41 to 11.01 over the past decade. While the company's 10-year median is 9.97 vs. the industry median of 10.17, Sichuan Kelun-Biotech Biopharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 10.17, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sichuan Kelun-Biotech Biopharmaceutical Co's current WACC % of 10.97% is 7.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. For the Biotechnology industry, the median WACC % is 10.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sichuan Kelun-Biotech Biopharmaceutical Co's current WACC % is 10.97%, which is 10% above median its own 10-year median of 9.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Kelun-Biotech Biopharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$254.91, compared to a current price of HK$523.00 — trading 105.2% above its estimated fair value. The current WACC % is 10.97%, which is 10% above median its 10-year median of 9.97 and 7.9% above the Biotechnology industry median of 10.17. Sichuan Kelun-Biotech Biopharmaceutical Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990), the current WACC % is 10.97% as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Overvalued in 2026?

Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co stock appears to be overvalued. The current stock price of HK$523.00 is trading 105.2% above its estimated GF Value™ of HK$254.91. GuruFocus considers Sichuan Kelun-Biotech Biopharmaceutical Co to be Significantly Overvalued.

Key valuation signals for HKSE:06990:

  • WACC %: 10.97% (10% above median its 10-year median of 9.97)
  • GF Value™: HK$254.91 vs. price of HK$523.00 (105.2% above fair value)
  • GF Score™: 44/100 with 4 warning signs
  • Industry Position: 7.9% above the Biotechnology median (#900 of 1421)

No single metric tells the full story. See the HKSE:06990 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sichuan Kelun-Biotech Biopharmaceutical Co Business Description

Address No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Currently, the company has two ADC drugs as Core Products, namely, sac-TMT and trastuzumab botidotin.
44GF Score

Get the complete analysis for HKSE:06990

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$523.00
Price
HK$254.91
GF Value